Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease
Identifieur interne : 002B35 ( Main/Corpus ); précédent : 002B34; suivant : 002B36Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease
Auteurs : Michael S. Okun ; Anthony Lang ; Joseph JankovicSource :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
Url:
DOI: 10.1002/mds.23021
Links to Exploration step
ISTEX:F94B7C300C6BE8519E0E67511772AE7C00D019C2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name><affiliation><mods:affiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F94B7C300C6BE8519E0E67511772AE7C00D019C2</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23021</idno><idno type="url">https://api.istex.fr/document/F94B7C300C6BE8519E0E67511772AE7C00D019C2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title><author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name><affiliation><mods:affiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15">2010-05-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="961">961</biblScope><biblScope unit="page" to="962">962</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F94B7C300C6BE8519E0E67511772AE7C00D019C2</idno><idno type="DOI">10.1002/mds.23021</idno><idno type="ArticleID">MDS23021</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Michael S. Okun MD</name><affiliations><json:string>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</json:string></affiliations></json:item><json:item><name>Anthony Lang MD</name><affiliations><json:string>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Joseph Jankovic MD</name><affiliations><json:string>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item></author><articleId><json:string>MDS23021</json:string></articleId><language><json:string>eng</json:string></language><qualityIndicators><score>5.012</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>0</abstractCharCount><pdfWordCount>5016</pdfWordCount><pdfCharCount>33248</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>1</abstractWordCount></qualityIndicators><title>Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title><genre><json:string>review-article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>2</total><last>962</last><first>961</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Letter to the Editor</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23021</json:string></doi><id>F94B7C300C6BE8519E0E67511772AE7C00D019C2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F94B7C300C6BE8519E0E67511772AE7C00D019C2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F94B7C300C6BE8519E0E67511772AE7C00D019C2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F94B7C300C6BE8519E0E67511772AE7C00D019C2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title><author><persName><forename type="first">Michael S.</forename><surname>Okun</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</p></note><affiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</affiliation></author><author><persName><forename type="first">Anthony</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><affiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Jankovic</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="961">961</biblScope><biblScope unit="page" to="962">962</biblScope></imprint></monogr><idno type="istex">F94B7C300C6BE8519E0E67511772AE7C00D019C2</idno><idno type="DOI">10.1002/mds.23021</idno><idno type="ArticleID">MDS23021</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Letter to the Editor</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-05-15">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F94B7C300C6BE8519E0E67511772AE7C00D019C2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v25:7</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2010-05-15">15 May 2010</coverDate></publicationMeta><publicationMeta level="unit" type="letter" position="300" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23021</doi><idGroup><id type="unit" value="MDS23021"></id></idGroup><countGroup><count type="pageTotal" number="2"></count></countGroup><titleGroup><title type="articleCategory">Letter to the Editor</title><title type="tocHeading1">Letters to the Editor Related to Published Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2010-04-13"></event><event type="publishedOnlineFinalForm" date="2010-05-05"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-04-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-08-12"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">961</numbering><numbering type="pageLast">962</numbering></numberingGroup><correspondenceTo>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23021.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="2"></count><count type="wordTotal" number="930"></count></countGroup><titleGroup><title type="main" xml:lang="en">Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Letters to the Editor</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Michael S.</givenNames><familyName>Okun</familyName><degrees>MD</degrees></personName><contactDetails><email>okun@neurology.ufl.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Anthony</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation></affiliationGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Letters to the Editor</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Michael S.</namePart><namePart type="family">Okun</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</affiliation><description>Correspondence: Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="letter"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-05-15</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">2</extent><extent unit="words">930</extent></physicalDescription><note type="content">*Potential conflict of interest: None reported</note><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Letter to the Editor</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>961</start><end>962</end><total>2</total></extent></part></relatedItem><identifier type="istex">F94B7C300C6BE8519E0E67511772AE7C00D019C2</identifier><identifier type="DOI">10.1002/mds.23021</identifier><identifier type="ArticleID">MDS23021</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002B35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:F94B7C300C6BE8519E0E67511772AE7C00D019C2
|texte= Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |